Department of Health and Social Management, University of Eastern Finland, Kuopio, Finland.
Information and Development Services Unit, Finnish Medicines Agency, Helsinki, Finland.
Age Ageing. 2023 Jun 1;52(6). doi: 10.1093/ageing/afad094.
Up to 90% of people with dementia experience behavioural and psychological symptoms of dementia (BPSD) as part of their illness. Psychotropics are not recommended as the first-line treatment of BPSD because older people are more prone to adverse reactions. In this study, we evaluate the impact of the Finnish clinical guidelines of BPSD (published in 2017) on psychotropic use in people with dementia.
This study is based on Finnish Prescription Register data from 2009 to 2020. The data included all community-dwelling Finnish people aged ≥65 and who had anti-dementia medication purchases (n = 217,778). We used three-phased interrupted time series design to evaluate the changes in levels and trends of monthly (n = 144) psychotropic user rates compared with the predicted trends. In addition, we evaluated the changes in levels and trends of monthly new psychotropic user rates.
The level of monthly psychotropic user rate decreased non-significantly during the intervention period (β -0.057, P = 0.853), and during the post-intervention period, there was an increase in the level (β 0.443, P = 0.091) and slope (β 0.199, P = 0.198), but not statistically significant. The level of monthly new psychotropic user rate (β -0.009, P = 0.949) during the intervention period and the level (β 0.044, P = 0.714) and slope (β 0.021, P = 0.705) during the post-intervention period were almost unchanged.
Results may indicate possible challenges in deprescribing and better adherence to the guidelines at the beginning of BPSD treatment. Further research into the barriers to implement BPSD guidelines and the availability of non-pharmacological treatments is needed.
高达 90%的痴呆症患者在其疾病过程中会经历行为和心理症状的痴呆症(BPSD)。由于老年人更容易出现不良反应,因此不建议将精神药物作为 BPSD 的一线治疗药物。在这项研究中,我们评估了 2017 年发布的芬兰 BPSD 临床指南对痴呆症患者使用精神药物的影响。
本研究基于 2009 年至 2020 年芬兰处方登记处的数据。该数据包括所有年龄在 65 岁及以上且有抗痴呆药物购买记录的居住在社区的芬兰人(n=217778)。我们使用三阶段中断时间序列设计来评估与预测趋势相比,每月(n=144)精神药物使用者比率的水平和趋势变化。此外,我们还评估了每月新精神药物使用者比率的水平和趋势变化。
干预期间,每月精神药物使用者比率的水平呈非显著下降(β=-0.057,P=0.853),而在干预后期间,水平(β=0.443,P=0.091)和斜率(β=0.199,P=0.198)有所增加,但无统计学意义。干预期间每月新精神药物使用者比率的水平(β=-0.009,P=0.949)和干预后期间的水平(β=0.044,P=0.714)和斜率(β=0.021,P=0.705)几乎不变。
结果可能表明在 BPSD 治疗开始时,减少药物治疗和更好地遵循指南可能存在挑战。需要进一步研究实施 BPSD 指南的障碍以及非药物治疗的可及性。